Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year
Up Next
No results found.